SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-14-386374
Filing Date
2014-10-29
Accepted
2014-10-29 09:59:01
Documents
6
Period of Report
2014-10-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d810667d8k.htm 8-K 21279
2 EX-1.1 d810667dex11.htm EX-1.1 183699
3 EX-3.1 d810667dex31.htm EX-3.1 4747
4 EX-5.1 d810667dex51.htm EX-5.1 5120
5 EX-99.1 d810667dex991.htm EX-99.1 7461
6 GRAPHIC g810667g20e03.jpg GRAPHIC 14065
  Complete submission text file 0001193125-14-386374.txt   243110
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 141178915
SIC: 2834 Pharmaceutical Preparations